Bryant J - Search Results

1

Calculation of lytic units for the expression of cell-mediated cytotoxicity.

Bryant J, Day R, Whiteside TL, Herberman RB. Bryant J, et al. J Immunol Methods. 1992 Jan 21;146(1):91-103. doi: 10.1016/0022-1759(92)90052-u. J Immunol Methods. 1992. PMID: 1735786

2

Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases.

Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH. Yang Q, et al. Int J Cancer. 2003 Jul 1;105(4):512-9. doi: 10.1002/ijc.11119. Int J Cancer. 2003. PMID: 12712443 Free article.

3

Measurements of Natural Killer (NK) Activity and NK-Cell Quantification.

Friberg DD, Bryant JL, Whiteside TL. Friberg DD, et al. Methods. 1996 Apr;9(2):316-26. doi: 10.1006/meth.1996.0037. Methods. 1996. PMID: 8812685

4

Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy.

Dignam J, Bryant J, Paik S. Dignam J, et al. Among authors: bryant j. Methods Mol Biol. 2002;184:169-89. doi: 10.1385/1-59259-242-2:169. Methods Mol Biol. 2002. PMID: 11889713 Review. No abstract available.

5

Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.

Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB, et al. Whiteside TL, et al. Among authors: bryant j. Cancer Res. 1993 Dec 1;53(23):5654-62. Cancer Res. 1993. PMID: 8242620

6

Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer.

Agarwala SS, Kirkwood JM, Bryant J. Agarwala SS, et al. Among authors: bryant j. Cytokines Cell Mol Ther. 2000 Dec;6(4):171-6. doi: 10.1080/mccm.6.4.171.176. Cytokines Cell Mol Ther. 2000. PMID: 11565955 Clinical Trial.

7

Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.

Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL. Kirkwood JM, et al. Among authors: bryant j. J Immunother. 1997 Mar;20(2):146-57. doi: 10.1097/00002371-199703000-00007. J Immunother. 1997. PMID: 9087387 Clinical Trial.

8

Incorporating toxicity considerations into the design of two-stage phase II clinical trials.

Bryant J, Day R. Bryant J, et al. Biometrics. 1995 Dec;51(4):1372-83. Biometrics. 1995. PMID: 8589229

9

Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay.

Whiteside TL, Bryant J, Day R, Herberman RB. Whiteside TL, et al. Among authors: bryant j. J Clin Lab Anal. 1990;4(2):102-14. doi: 10.1002/jcla.1860040207. J Clin Lab Anal. 1990. PMID: 2179501 Review.

10

Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

Jain AB, Todo S, Fung JJ, Venkataramanan R, Day R, Bryant J, Abu-Elmagd KM, Alessiani M, Takaya S, Tzakis A, et al. Jain AB, et al. Among authors: bryant j. Transplant Proc. 1991 Dec;23(6):3023-5. Transplant Proc. 1991. PMID: 1721347 Free PMC article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results